Related references
Note: Only part of the references are listed.Breast cancer and cytomegalovirus
A. K. Richardson et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
A critical review of the relationship between post-transplant atherosclerotic events and cytomegalovirus exposure in kidney transplant recipients
Isabel Rodriguez-Goncer et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
Cytomegalovirus Infection Is a Risk Factor in Gastrointestinal Cancer: A Cross-Sectional and Meta-Analysis Study
Ya-li Lv et al.
INTERVIROLOGY (2020)
Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
Alexandre Jentzer et al.
MICROORGANISMS (2020)
New acetamide derivatives containing (ω-p-bromophenoxyalkyl)uracil moiety and their anticytomegalovirus activity
Maria P. Paramonova et al.
MENDELEEV COMMUNICATIONS (2020)
Synthesis and Antiviral Properties of 1-Substituted 3-[(ω-(4-Oxoquinazolin-4(3H)-yl)alkyl]uracil Derivatives
M. P. Paramonova et al.
ACTA NATURAE (2020)
Vaccination against the human cytomegalovirus
Stanley A. Plotkin et al.
VACCINE (2019)
Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance
Jocelyne Piret et al.
ANTIVIRAL RESEARCH (2019)
Updates on antiviral drugs for cytomegalovirus prevention and treatment
Camille N. Kotton
CURRENT OPINION IN ORGAN TRANSPLANTATION (2019)
Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
Guy El Helou et al.
INFECTION AND DRUG RESISTANCE (2019)
Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
Genovefa A. Papanicolaou et al.
CLINICAL INFECTIOUS DISEASES (2019)
Case report: Brincidofovir-induced reversible severe acute kidney injury in 2 solid-organ transplant for treatment of cytomegalovirus infection
Emmanuel Faure et al.
MEDICINE (2016)
Toward the discovery of dual HCMV-VZV inhibitors: Synthesis, structure activity relationship analysis, and cytotoxicity studies of long chained 2-uracil-3-yl-N-(4-phenoxyphenyl)acetamides
Denis A. Babkov et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Synthesis and anti-HCMV activity of 1-[ω-(phenoxy)alkyl]uracil derivatives and analogues thereof
Mikhail S. Novikov et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase
Mikhail S. Novikov et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Therapeutic strategies for the prevention and treatment of cytomegalovirus infection
Rob S. Sellar et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Cytomegalovirus and immune senescence: Culprit or innocent bystander?
Urs Karrer et al.
EXPERIMENTAL GERONTOLOGY (2009)
Antiviral activity of 3-(3,5-dimethylbenzyl)uracil derivatives against HIV-1 and HCMV
Tokumi Maruyama et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2007)
Share Paper
